Tim Wilsdon is speaking during the conference in a session titled “Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements.”
For more information on this event, click here.
From ASP to MFP: The looming disruption of the medical benefit
Key recent developments in the program include: The first two years of the MDPNP only covered retail-dispensed therapies but starting in this selection...